Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including ...
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback